Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 2/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.45 |
| ▸ | HTR3B | O95264 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.45 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11632239 | 0.93 | BCHE (0.46) | F2LMNABCHECHRNA7KMT2A | |
| SCHEMBL27526040 | 0.87 | F2 (0.47) | F2LMNABCHECHRNA7KMT2A | |
| SCHEMBL27875017 | 0.82 | LMNA (0.54) | F2LMNABCHECHRNA7KMT2A | |
| SCHEMBL5216010 | 0.80 | TDP1 (0.50) | LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL2574686 | 0.79 | CHRNA7 (0.50) | F2LMNABCHECHRNA7KMT2A | |
| SCHEMBL10338863 | 0.78 | BCHE (0.53) | F2LMNABCHECHRNA7KMT2A | |
| SCHEMBL2573686 | 0.78 | PTPN1 (0.42) | LMNABCHECHRNA7MAPTSMN1; SMN2 | |
| SCHEMBL11245395 | 0.78 | BCHE (0.46) | F2LMNABCHECHRNA7KMT2A | |
| SCHEMBL10995636 | 0.77 | BCHE (0.51) | F2LMNABCHECHRNA7KMT2A | |
| SCHEMBL2568789 | 0.76 | PTPN1 (0.39) | BCHEKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-58134089-A | — | — | None | — | — | JP | disclosed |
| CN-115028637-B | Triazolopyrimidine compounds and their use for the treatment of cancer | 迪哲(江苏)医药股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-111655255-A | Composition for preventing or treating neurodegenerative disease comprising diterpenoid compound | 韩国生命工学研究院 | 2020-09-11 | — | — | CN | disclosed |
| EP-1720840-B1 | METHODS TO MANUFACTURE 1,3-DIOXOLANE NUCLEOSIDES | UNIV EMORY (US) | 2016-02-03 | — | — | EP | disclosed |
| US-8420354-B2 | Methods to manufacture 1,3-dioxolane nucleosides | EMORY UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110130559-A1 | Methods to Manufacture 1,3-Dioxolane Nucleosides | GILEAD SCIENCES, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-7785839-B2 | Methods to manufacture 1,3-dioxolane nucleosides | EMORY UNIVERSITY (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1720840-A4 | METHODS TO MANUFACTURE 1,3-DIOXOLANE NUCLEOSIDES | UNIV EMORY (US) | 2009-01-21 | — | — | EP | disclosed |
| EP-1720840-A2 | METHODS TO MANUFACTURE 1,3-DIOXOLANE NUCLEOSIDES | EMORY UNIVERSITY (US) | 2006-11-15 | — | — | EP | disclosed |
| US-20060036092-A1 | Methods to manufacture 1,3-dioxolane nucleosides | SZNAIDMAN MARCOS | 2006-02-16 | — | — | US | disclosed |
| WO-2005074654-A2 | METHODS TO MANUFACTURE 1,3-DIOXOLANE NUCLEOSIDES | EMORY UNIVERSITY (US) | 2005-08-18 | — | — | WO | disclosed |
| JP-S58134089-A | 1,3-DIOXOLANE BENZOATE DERIVATIVE AND PREPARATION THEREOF | HAMADA YOSHIKI | 1983-08-10 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060036092-A1 | Methods to manufacture 1,3-dioxolane nucleosides | DCTD, AMPD1, DAD1 | F2 2918/4885LMNA 260/4885BCHE 2637/4885 |
| US-20110130559-A1 | Methods to Manufacture 1,3-Dioxolane Nucleosides | DCTD, AMPD1, DAD1 | F2 3094/4885LMNA 266/4885BCHE 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.